1 citations
,
July 2021 in “Current nanomedicine” The new gel formulation for Acitretin improves topical delivery and reduces oral toxicity.
February 2025 in “Indian Dermatology Online Journal” Calcipotriol is the safest and most effective for hair regrowth in localized alopecia areata.
21 citations
,
April 2008 in “Toxicologic Pathology” CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.
1 citations
,
February 2025 in “International Journal of Dermatology” Abrocitinib may effectively treat Lichen Planopilaris.
July 2024 in “Journal of Investigative Dermatology” 96 citations
,
December 2015 in “JAMA dermatology” Topical Ruxolitinib may safely treat severe hair loss.
Baricitinib is more effective than methotrexate for severe alopecia areata.
September 2024 in “Dermatology Reports” Sonidegib often causes hair loss, and LC-OCT helps identify early signs.
October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
39 citations
,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
80 citations
,
June 2012 in “European Journal of Pharmaceutics and Biopharmaceutics” Nanoparticles improve drug delivery and effectiveness in treating inflamed skin.
1 citations
,
August 2023 in “JAMA Dermatology” Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
2 citations
,
June 2020 in “Clinical Journal of Gastroenterology” Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.
November 2023 in “SKIN The Journal of Cutaneous Medicine”
24 citations
,
July 2018 in “Drug Design Development and Therapy” NTF gel improves finasteride delivery for hair loss treatment, reducing side effects.
9 citations
,
February 2022 in “European Journal of Pharmaceutics and Biopharmaceutics” A new treatment for hair loss uses tiny lipid carriers to deliver a mix of minoxidil and latanoprost directly to hair follicles, promoting hair growth and being well tolerated by the skin.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
April 2017 in “Journal of Investigative Dermatology” SIG-1451 could be a promising new treatment for atopic dermatitis.
January 2024 in “Skin Research and Technology” Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.
May 2025 in “Journal of Pharmacy And Bioallied Sciences” Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
37 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Ruxolitinib can help regrow hair in severe alopecia areata.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
5 citations
,
December 2023 in “Journal of the European Academy of Dermatology and Venereology” 59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
March 2020 in “Case medical research”
9 citations
,
February 2011 in “Biologics: Targets & Therapy” Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.
2 citations
,
March 2023 in “Frontiers in medicine” A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.